Envestnet Asset Management Inc. Sells 3,145 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Envestnet Asset Management Inc. trimmed its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 117,527 shares of the medical equipment provider’s stock after selling 3,145 shares during the quarter. Envestnet Asset Management Inc. owned about 0.17% of Lantheus worth $10,514,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of LNTH. HighTower Advisors LLC acquired a new position in Lantheus during the 3rd quarter valued at about $607,000. MML Investors Services LLC grew its stake in shares of Lantheus by 24.6% during the third quarter. MML Investors Services LLC now owns 4,338 shares of the medical equipment provider’s stock worth $476,000 after acquiring an additional 857 shares during the last quarter. World Investment Advisors LLC purchased a new stake in shares of Lantheus during the third quarter worth about $60,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Lantheus during the third quarter valued at about $25,000. Finally, Tidal Investments LLC raised its position in shares of Lantheus by 25.2% in the 3rd quarter. Tidal Investments LLC now owns 17,621 shares of the medical equipment provider’s stock valued at $1,934,000 after purchasing an additional 3,547 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. B. Riley cut their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Truist Financial raised their target price on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Finally, JMP Securities reiterated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $129.43.

Lantheus Price Performance

LNTH stock opened at $101.32 on Friday. Lantheus Holdings, Inc. has a 1 year low of $61.47 and a 1 year high of $126.89. The firm has a market capitalization of $6.94 billion, a PE ratio of 16.86 and a beta of 0.20. The business has a 50 day simple moving average of $95.00 and a 200-day simple moving average of $95.55.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. On average, equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.